Imaradenant

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameImaradenant
Drug Alias NameAZD-4635HTL-1071
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionG-protein coupled receptor modulatorsC-C chemokine receptors antagonistsAdenosine A2a receptor antagonists
TargetsG-protein coupled receptorC-C chemokine receptorsAdenosine A2a receptor
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNxera Pharma UK Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcMedimmune Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A